First Coast Services Options Now Covering Amniox Medical Products

NEOX® Wound Allograft Accessible to More than 2.5 Million Additional Medicare Lives

Nov 16, 2015, 06:00 ET from AMNIOX Medical, Inc.

ATLANTA, Nov. 16, 2015 /PRNewswire/ -- AMNIOX Medical, Inc., a TissueTech, Inc. company, announced First Coast Services Options, Inc. will provide Medicare coverage for its NEOX ® Wound Matrix, including the only umbilical cord allograft available to clinicians to treat chronic, non-healing wounds.

Medicare covers the majority of patients with chronic wounds that are appropriate for treatment with umbilical cord. First Coast is the Medicare Administrative Contractor that adjudicates claims in Florida, Puerto Rico and the U.S. Virgin Islands. This jurisdiction includes more than 2.5 million lives covered by Medicare and is responsible for approximately 8% of total Medicare claims. Since April 2015, Novitas Solutions and Noridian Healthcare Solutions also implemented similar positive reimbursement policies related to the use of umbilical cord and amniotic membrane products to promote wound healing. Including First Coast, 50% of lives covered by Medicare nationwide now have access to Amniox products. 

Amniox parent TissueTech pioneered the clinical application of human umbilical cord and amniotic membrane to promote rapid, scar-less healing that occurs in utero to wounds in adults. Since the company's inception, clinicians have performed more than 200,000 human transplants of its products and published more than 300 peer-reviewed studies supporting its technology platform.  Amniox Medical was formed in 2011 to focus on the orthopedic and wound care markets.    

"This growth in Medicare coverage reflects increasing payer acknowledgment of the product's benefits, as well as greater adoption among healthcare providers," said Thomas J. Dugan, CEO of Amniox. "Amniox is committed to expanding access to this remarkable therapy for wound care clinicians and their patients, and we are investing significant resources to obtain coverage for the patients who can benefit from it most."

In utero, wound healing occurs rapidly and with minimal scar. This restorative ability is innate to placental tissues, including umbilical cord and amniotic membrane. Heavy chain hyaluronic acid/pentraxin-3 is the key protein complex present in these tissues to orchestrate the healing process. Amniox Medical is the only provider of a human tissue allograft composed of both umbilical cord and amniotic membrane. Amniox utilizes its proprietary CryoTek® process, a cryopreservation technology, to preserve the biological and structural integrity of the native tissue and published studies have demonstrated that the CryoTek process more effectively preserves the structural integrity and biological signaling molecules that are present.

About Amniox Medical, Inc.

Founded in 2011 to serve the orthopedic and wound care markets, Amniox Medical is dedicated to developing and marketing regenerative therapies processed from umbilical cord and amniotic membrane utilizing its proprietary CryoTek technology. This process has been proven to preserve the innate biological and structural properties of the matrix, which can then be transplanted to adult wound and surgical environments. Amniox Medical procures its tissue through elective donation following healthy live birth via Cesarean section. Thorough donor screening is performed to ensure safety of its products. For additional information, please visit

About TissueTech, Inc.

TissueTech, Inc., the parent company of Amniox Medical, Inc. and BioTissue, Inc., pioneered the development and clinical application of regenerative, amniotic tissue-based products. Amniox Medical develops and markets products for use in the musculoskeletal and wound care markets; BioTissue develops and markets products for the ophthalmology and optometry markets. The National Institutes of Health (NIH) has supported TissueTech's research with more than 25 continuous years of research grants. Since the company's inception, clinicians have performed more than 200,000 human implants of the company's products and published more than 300 peer-reviewed studies supporting its technology platform. The Company's first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation.